Raas Heart Failure Mechanisms Therapeutic Targets

RAAS

The RAAS helps in regulating blood pressure and fluid balance. In heart failure, the reduced cardiac output and systemic blood pressure stimulate the RAAS as a compensatory mechanism, which in turn leads to increased retention of sodium and water, vasoconstriction, and elevated blood pressure. This activation of the RAAS is at first adaptive, but it basically contributes to the progression of heart failure and exacerbates atherosclerosis by promoting endothelial dysfunction, inflammation, and vascular remodeling.

It works this way: in response to heart failure, the RAAS system is activated as a compensatory mechanism (Pugliese et al., 2020). The process begins when the kidneys, sensing reduced blood flow and pressure, release the enzyme renin into the bloodstream. Renin converts angiotensinogen, a liver-produced protein, into angiotensin I, which is then converted into angiotensin II by angiotensin-converting enzyme (ACE) primarily in the lungs. Angiotensin II is a potent vasoconstrictor, which increases blood pressure by narrowing blood vessels (Senatore et al., 2021). Additionally, it stimulates the secretion of aldosterone from the adrenal glands, leading to sodium and water retention by the kidneys, thereby increasing blood volume and pressure.

However, although the initial activation of the RAAS serves to maintain blood pressure and perfusion in the face of decreased cardiac output, chronic activation has negative side effects, such as increased blood pressure (Senatore et al., 2021). Chronic vasoconstriction and fluid retention elevate blood pressure, which imposes additional workload on the heart, exacerbating heart failure. Moreover, angiotensin II contributes to endothelial dysfunction, impairing the ability of blood vessels to dilate, which further elevates blood pressure and compromises blood flow to various organs. RAAS components, especially angiotensin II, have been shown to promote inflammation and oxidative stress, pivotal factors in the development of atherosclerosis. Atherosclerosis can lead to further cardiovascular events and worsen heart failure outcomes. Angiotensin II also stimulates the growth of smooth muscle cells and the production of extracellular matrix in the vessel walls, leading to vascular remodeling. This process narrows the arteries and reduces their elasticity, contributing to the progression of hypertension and atherosclerosis (Pugliese et al., 2020).

Recent studies offer insights into these mechanisms and propose potential therapeutic targets. Romero-González et al. (2024), for example, show how heart failure, even in patients with normal Glomerular Filtration Rate (GFR), is linked to alterations in the RAAS and contributes to the progression of atherosclerosis through various pathways, including the exacerbation of endothelial dysfunction and promoting inflammatory processes??. Laranjo et al. (2024) discuss the significance of managing and understanding the interplay between heart failure and atherosclerosis.

Understanding the role of RAAS in heart failure and atherosclerosis has led to the development of therapeutic strategies aimed at inhibiting this system to improve outcomes in patients with cardiovascular diseases. Medications such as ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) target different components of the RAAS, offering benefits such as reduced blood pressure, decreased risk of atherosclerotic events, and mitigation of heart failure progression.

Overall, the RAAS is important in the body\\\\\\\'s initial response to heart failure, but its chronic activation contributes significantly to the pathology of heart failure and atherosclerosis through mechanisms such as endothelial dysfunction, inflammation, and vascular remodeling. Targeting the RAAS therapeutically has become a cornerstone in managing these conditions, which shows the importance of this system in cardiovascular health.